Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Debio 1454S
- Development stage
- Preclinical
- Lead developer
- Debiopharm
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Debio 1454S is a preclinical, pathogen-specific antibiotic being developed by Debiopharm. It acts as a first-in-class inhibitor of FabI (enoyl-acyl carrier protein reductase), an essential enzyme in the bacterial fatty acid biosynthesis pathway. The drug is specifically designed for the intravenous treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii. Due to its targeted spectrum of activity, it possesses microbiome-sparing potential, which is a significant advantage in preventing the development of antimicrobial resistance (AMR).
02
Targets
InhA
Beyond the preview
Go deeper on Debio 1454S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Debio 1454S.